Since there is no sun in Berlin anyways, we thought we might as well travel up north to Sweden to visit NeuroVive Pharmaceuticals. The company is located in the university town of Lund and is focussing on the development of compounds that target mitochondria, the cell’s powerhouses.
Mission: NeuroVive is tackling a broad variety of diseases involving both traditional hereditary mitochondrial disorders such as mitochondrial myopathies and complex I dysfunctions, as well as non-traditional disorders including traumatic brain injury (TBI). Its lead candidate NeuroSTAT is currently in Phase II clinical development and consists of a formulation of the natural immunosuppressant ciclosporin. The compound is able to stabilize mitochondria through the inhibition of the mitochondrial protein cyclophilin D, thereby protecting from neuronal cell death and limiting the spread of brain injury. Neurovive has been able to snatch orphan drug designation for the compound both in the EU and the US.
Comment: The company’s stock fiercely dropped last year in October, after its ciclosporin-formulation CicloMulsion flopped in clinical trials for the treatment of patients with myocardial infarction. Now the company seems to be getting back on its feet to position its non-immunosuppressive cyclophilin D inhibitor as a first-in-class treatment for NASH. Additionally, the company is expanding into the field of hepatocellular carcinoma, adding the liver diseases to the company’s repertoire of non-traditional mitochondrial diseases.
Images via shutterstock.com / NoPainNoGain / Stig Alenas